B6068-100mg | Deferoxamine mesylate [138-14-7] Biotrend

Background

Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]

Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions. The formed chelate is readily soluble in water and passes easily through the kidney [1].

In Fisher rats transplanted with the 13762NF mammary adenocarcinoma, deferoxamine mesylate reduced rat tumor growth. While deferoxamine mesylate?injections plus a low iron diet caused the greatest inhibitory effect on tumor growth. Deferoxamine mesylate may be a useful chemotherapeutic agent in the treatment of breast cancer [2]. In Sprague-Dawley rats, injected with deferoxamine mesylate (75-90 mg; 300 mg/kg) via the celiac artery before surgery. Deferoxamine mesylate signi?cantly lowered the serum levels of amylase, lipase, and malondialdehyde (MDA) after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1 protein and inhibition of oxidative toxic reactions [3].

References:
Deferoxamine mesylate (Desferal mesylate). A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):595-6.
Wang F, Elliott RL, Head JF. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999 Jan-Feb;19(1A):445-50.
Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011 Jun;43(5):1450-5.

Product Citation

1. Wei Huang, Gaowen Qu, et al. "Kallistatin enhances the phagocytic function of macrophages by decreasing the expression of CD24 in gastric cancer cells via the HIF-1α signaling pathway." bioRxiv. 05 Apr, 2024.
2. Hao Zheng, Jinming Liu, et al. "Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance." Nat Cancer. 2024 Jan 30. PMID: 38291304
3. Qianping Zhang, Tiantian Sun, et al. "PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury." Nat Chem Biol. 2024 Jan 29. PMID: 38287154
4. Zhijing He, He Zhou, et al. "A bimetallic dual-targeting nanoplatform for combinational ferroptosis activation/epigenetic regulation/photothermal therapy against breast cancer and tumor microenvironment remodeling." Chemical Engineering Journal Volume 479, 1 January 2024, 147466.
5. Mingchao Mu, Qin Zhang, et al. "3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis." Cancer Gene Ther. 2023 Aug 9. PMID: 37558749
6. Yu Zhang, Xiyou Du, et al. "A Vanadium-Based Nanoplatform Synergizing Ferroptotic-like Therapy with Glucose Metabolism Intervention for Enhanced Cancer Cell Death and Antitumor Immunity." ACS Nano. 2023 Jun 5. PMID: 37272777
7. Fan Yu, Qianping Zhang, et al. "Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis." Cell Discov. 2022 May 3;8(1):40. PMID: 35504898
8. Binghua Liu, Weiyan Wang, et al. "Sodium iodate induces ferroptosis in human retinal pigment epithelium ARPE-19 cells." Cell Death Dis. 2021 Mar 3;12(3):230. PMID: 33658488
9. Junhong Zhang, Ni Wang, et al. "Oridonin induces ferroptosis by inhibiting gamma‐glutamyl cycle in TE1 cells." Phytother Res 2020 Aug 31. PMID: 32869425
10. Tianshu Wu, Xue Liang, et al. "Induction of ferroptosis in response to graphene quantum dots through mitochondrial oxidative stress in microglia." Part Fibre Toxicol. 2020 Jul 11;17(1):30. PMID: 32652997

Hide ↑↑

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	656.79
Cas No.	138-14-7
Formula	C₂₆H₅₂N₆O₁₁S
Solubility	≥65.7 mg/mL in H2O; insoluble in EtOH; ≥29.8 mg/mL in DMSO
Chemical Name	(Z)-4-((5-aminopentyl)(hydroxy)amino)-N-(5-((Z)-N,4-dihydroxy-4-((5-(N-hydroxyacetamido)pentyl)imino)butanamido)pentyl)-4-oxobutanimidic acid compound with methanesulfonic acid (1:1)
SDF	Download SDF
Canonical SMILES	CC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCCN)=O)=O)=O.CS(O)(=O)=O
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]
Cell lines	Adipose derived mesenchymal stem cells (AdMSCs)
Reaction Conditions	30, 60 or 120 μM deferoxamine mesylate for 12 h inubation
Applications	Cells exposed to 30 or 60 μM of deferoxamine mesylate showed significantly lower expression of hypoxia-inducible factor-1α (HIF-1α) when compared with cells cultured under 1% O2, but cell treated with 120 μM deferoxamine mesylate was able to mimic cells under hypoxic conditions. Deferoxamine mesylate could promote wound healing in AdMSCs through HIF-1α stabilization.
Animal experiment:[2]
Animal models	Sprague-Dawley rats, 0.25 ~ 0.30 kg
Dosage form	75 ~ 90 mg; 300 mg/kg Injected via the celiac artery at 24 and 48 hours before orthotopic liver autotransplantation
Applications	Deferoxamine mesylate significantly lowered the serum levels of amylase, lipase, and malondialdehyde after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1α protein and inhibition of oxidative toxic reactions.
Note	The technical data provided above is for reference only.
	References: 1. Wahl EA, Schenck TL, Machens HG, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Scientific Reports, 2016, 6: 36879. 2. Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplantation Proceedings, 2011, 43(5): 1450-1455.

Quality Control

Purity = 98.00%

Deferoxamine mesylate [138-14-7]

Cat# B6068-100mg

Contact local distributor :

Brand : APExBIO Technology